License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended September 30,				Nine months ended September 30,
Partner	Drug or Drug Candidate	2016		2015		2016		2015
AstraZeneca AB	MOVANTIKTM and MOVANTIKTM fixed-dose combination program	$	3,000	$	40,000	$	31,000	$	130,000
Roche	PEGASYS® and MIRCERA®		1,929		3,212		5,771		9,619
Amgen, Inc.	Neulasta®		1,250		1,250		3,750		3,750
Daiichi Sankyo Europe GmbH	ONZEALDTM (NKTR-102)		216		—		3,474		—
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		357		357		1,072		1,562
Baxalta Incorporated	ADYNOVATETM		336		409		648		607
Other			1,285		1,247		5,114		3,885
License, collaboration and other revenue		$	8,373	$	46,475	$	50,829	$	149,423